Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ
Tytuł pozycji:

Policy responses to hepatitis C in the Nordic countries:Gaps and discrepant reporting in the Hep-Nordic study

Tytuł :
Policy responses to hepatitis C in the Nordic countries:Gaps and discrepant reporting in the Hep-Nordic study
Index Terms :
Cross-Sectional Studies
Hepatitis C/diagnosis
Humans
Prevalence
Public Health Practice
Scandinavian and Nordic Countries/epidemiology
Substance Abuse, Intravenous/complications
dk/atira/pure/researchoutput/pubmedpublicationtype/D016428
Journal Article
dk/atira/pure/researchoutput/pubmedpublicationtype/D013485
Research Support, Non-U.S. Gov't
article
Wydawca :
2018
Dodane szczegóły :
Safreed-Harmon, Kelly
Hetherington, Kristina L
Aleman, Soo
Alho, Hannu
Dalgard, Olav
Frisch, Tove
Gottfredsson, Magnus
Weis, Nina
Lazarus, Jeffrey V
Typ dokumentu :
Zasób elektroniczny
Dostępność :
Open access content. Open access content
info:eu-repo/semantics/openAccess
Pozostałe numery :
DAV oai:pure.atira.dk:publications/78e39c6f-b91f-4bfa-a48d-a2bde0d7f122
1085119216
Źródło wspomagające :
UNIV OF COPENHAGEN
From OAIster®, provided by the OCLC Cooperative.
Numer akcesji :
edsoai.on1085119216
Zasób elektroniczny
BACKGROUND AND AIMS: In the Nordic countries (Denmark, Finland, Iceland, Norway, Sweden), the prevalence of chronic hepatitis C virus (HCV) infection is relatively low in the general population, but is much higher among people who inject drugs (PWID). We conducted an exploratory study to investigate the extent to which these countries have policies supporting key elements of the public health response that is necessary to achieve the global goal of eliminating HCV as a public health threat.METHODS: Fourteen stakeholders representing government agencies, medical societies, and civil society organisations (CSOs) in the Nordic countries completed a cross-sectional online survey that included 21 policy questions related to national coordination, prevention, testing, linkage to care, and treatment. We summarised the findings in a descriptive analysis, and noted discrepant responses from stakeholders within the same country.RESULTS: Stakeholders reported that three of the five study countries have national viral hepatitis strategies, while only Iceland has a national HCV elimination goal. The availability of harm reduction services varies, with opioid substitution therapy provided for the general population throughout all countries, but not needle and syringe programmes. No country has access to anonymous HCV testing in all parts of the country. National HCV treatment guidelines are available in all countries except Finland, and all countries provide publicly funded direct-acting antiviral treatment. Disagreement regarding policies was observed across countries, and CSOs were the stakeholder group that most frequently answered survey questions incorrectly.CONCLUSION: The Nordic region as a whole has not consistently expressed its commitment to tackling HCV, despite the existence of large HCV epidemics among PWID in these countries. Stakeholder alignment and an established elimination goal with an accompanying strategy and implementation plan should

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies